Cargando…
Impact of interleukin-6 blockade with tocilizumab on SARS-CoV-2 viral kinetics and antibody responses in patients with COVID-19: A prospective cohort study
BACKGROUND: The virological and immunological effects of the immunomodulatory drugs used for COVID-19 remain unknown. We evaluated the impact of interleukin (IL)-6 blockade with tocilizumab on SARS-CoV-2 viral kinetics and the antibody response in patients with COVID-19. METHODS: Prospective cohort...
Autores principales: | Masiá, Mar, Fernández-González, Marta, Padilla, Sergio, Ortega, Piedad, García, José A., Agulló, Vanesa, García-Abellán, Javier, Telenti, Guillermo, Guillén, Lucía, Gutiérrez, Félix |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7492814/ https://www.ncbi.nlm.nih.gov/pubmed/32950003 http://dx.doi.org/10.1016/j.ebiom.2020.102999 |
Ejemplares similares
-
Preemptive interleukin-6 blockade in patients with COVID-19
por: Guillén, Lucía, et al.
Publicado: (2020) -
SARS-CoV-2 Seroconversion and Viral Clearance in Patients Hospitalized With COVID-19: Viral Load Predicts Antibody Response
por: Masiá, Mar, et al.
Publicado: (2021) -
Impact of the Addition of Baricitinib to Standard of Care Including Tocilizumab and Corticosteroids on Mortality and Safety in Severe COVID-19
por: Masiá, Mar, et al.
Publicado: (2021) -
Robust long-term immunity to SARS-CoV-2 in patients recovered from severe COVID-19 after interleukin-6 blockade
por: Masiá, Mar, et al.
Publicado: (2022) -
Durable antibody response one year after hospitalization for COVID-19: A longitudinal cohort study
por: Masiá, Mar, et al.
Publicado: (2021)